Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, covers the reporting date of May 22, 2026. The registrant is headquartered in Marseille, France, and files annual reports under Form 20-F.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a vehicle to distribute a press release (Exhibit 99.1) rather than a standalone financial statement.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. No comparative financial data is included in the provided document text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document references a press release dated May 22, 2026, which likely contains these details, but the content of that release is not included in the input text.
Key Facts for Investor Verification
- Verify the specific content of the Press Release dated May 22, 2026 (Exhibit 99.1), as the Form 6-K itself contains no operational or financial data.
- Confirm the identity of the signatory, Jonathan Dickinson, as the Chief Executive Officer.
- Note that the company operates under the regulatory framework of a Foreign Private Issuer filing Form 20-F.